Azithromycin Use in Pregnancy: Safety, Recommendations, and Precautions

Safety Profile

Azithromycin is classified as FDA Pregnancy Category B, indicating animal studies show no fetal harm and human data are limited but not suggestive of risk【1】.
Accumulated clinical experience and preliminary studies support that azithromycin is safe and effective for use in pregnant patients【5】.

The CDC recommends a single oral dose of azithromycin 1 g as a first‑line treatment for chlamydial infection in pregnancy【5】.
CDC 2006 guidelines list azithromycin 1 g single dose as the preferred regimen, with amoxicillin 500 mg three times daily for 7 days as an alternative【5】.
Earlier CDC guidance (1998, 2002) designated azithromycin only as an alternative option because data were considered insufficient for routine use【8】.
By 2006, growing clinical experience led the CDC to upgrade azithromycin to a recommended first‑line agent, reflecting increased confidence in its safety profile【5】.

Erythromycin estolate is absolutely contraindicated in pregnancy due to a risk of drug‑related hepatotoxicity【5】.
The antibiotics doxycycline, ofloxacin, and levofloxacin are contraindicated for use in pregnant women【5】.

The CDC advises repeat testing (culture or nucleic‑acid amplification test) ≈ 3 weeks after completing therapy to confirm cure in all pregnant patients treated for chlamydia【5】.
No pregnancy‑safe regimen achieves 100 % efficacy, underscoring the need for post‑treatment testing【6】.
Gastrointestinal side effects associated with erythromycin can reduce adherence, further supporting the need for follow‑up verification【5】.
Confirming therapeutic cure is essential to prevent maternal and neonatal complications【5】.

Counsel patients that azithromycin is generally better tolerated than erythromycin, with fewer reports of nausea, vomiting, diarrhea, and abdominal pain【1】.
Advise patients to avoid taking azithromycin concurrently with aluminum‑ or magnesium‑containing antacids, as these agents markedly decrease azithromycin absorption【1】.